EGFR and non-small cell lung carcinoma: It has been shown that EGFR-TKIs can significantly improve the clinical outcomes, including progression-free survival (PFS), disease-free survival (DFS) and overall survival (OS), of EGFR-positive NSCLC patients [3–5].